Related Experiment Video

Updated: Feb 5, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

Mechanistic insights into HAGLROS-mediated therapy resistance in ovarian cancer

Mohadeseh Sheykhi-Sabzehpoush1, Hamed Abedzeydi2, Maryam Khombi Shooshtari3

  • 1Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|February 3, 2026
PubMed

Insights

The long non-coding RNA HAGLROS promotes ovarian cancer by increasing proliferation and metastasis. Targeting HAGLROS and its microRNA interactions may offer new diagnostic and therapeutic strategies for this deadly cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer is a significant gynecological malignancy with poor prognosis due to late detection and treatment resistance.
  • Long non-coding RNAs (lncRNAs) are emerging as key players in cancer development and progression.
  • Understanding the role of specific lncRNAs in ovarian cancer pathogenesis is crucial for developing effective treatments.

Purpose of the Study:

  • To review and elucidate the molecular and functional roles of the lncRNA HAGLROS in ovarian cancer.
  • To focus on the involvement of HAGLROS within competing endogenous RNA (ceRNA) networks.
  • To explore HAGLROS as a potential biomarker and therapeutic target.

Main Methods:

  • Literature synthesis and review of current research on HAGLROS in ovarian cancer.
  • Analysis of HAGLROS's molecular mechanisms, including its interactions with microRNAs (miRNAs).
  • Examination of HAGLROS's role in regulating key cancer hallmarks such as proliferation, metastasis, and apoptosis.

Main Results:

  • HAGLROS (at 2q31.1) is an oncogenic lncRNA that significantly promotes ovarian cancer progression.
  • It enhances cell proliferation, metastasis, and chemotherapy resistance while inhibiting apoptosis.
  • HAGLROS exerts its oncogenic effects primarily through miRNA sponging, disrupting gene regulation and impacting epigenetic/transcriptional processes.

Conclusions:

  • Dysregulated HAGLROS plays a critical role in ovarian tumorigenesis and cancer hallmarks.
  • The HAGLROS-miRNA network represents a complex regulatory axis in ovarian cancer.
  • HAGLROS shows promise as a diagnostic biomarker and a target for novel therapeutic interventions in ovarian cancer.
Keywords:
Gynecological malignanciesHAGLROSOvarian cancerPathogenesisTherapeutic targetlncRNA

More Related Videos

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

34.6K
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.7K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
385
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.6K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
6.0K